A new trading day began on Monday, with UroGen Pharma Ltd (NASDAQ: URGN) stock price up 9.91% from the previous day of trading, before settling in for the closing price of $18.97. URGN’s price has ranged from $3.42 to $21.71 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 10.39% over the past five years. Meanwhile, its annual earnings per share averaged -7.37%. With a float of $42.38 million, this company’s outstanding shares have now reached $46.20 million.
UroGen Pharma Ltd (URGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 8.33%, while institutional ownership is 92.50%. The most recent insider transaction that took place on Oct 08 ’25, was worth 37,121. In this transaction Chief Financial Officer of this company sold 2,203 shares at a rate of $16.85, taking the stock ownership to the 2,280 shares. Before that another transaction happened on Sep 08 ’25, when Company’s Chief Medical Officer sold 871 for $19.11, making the entire transaction worth $16,645. This insider now owns 149,025 shares in total.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.55 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.37% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Here are UroGen Pharma Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.32, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd (NASDAQ: URGN) saw its 5-day average volume 0.96 million, a negative change from its year-to-date volume of 1.46 million. As of the previous 9 days, the stock’s Stochastic %D was 80.24%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 94.91%, which indicates a significant decrease from 97.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.06 in the past 14 days, which was lower than the 1.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.41, while its 200-day Moving Average is $13.31. Nevertheless, the first resistance level for the watch stands at $21.57 in the near term. At $22.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.57. If the price goes on to break the first support level at $19.57, it is likely to go to the next support level at $18.28. Assuming the price breaks the second support level, the third support level stands at $17.57.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
With a market capitalization of 964.61 million, the company has a total of 46,264K Shares Outstanding. Currently, annual sales are 90,400 K while annual income is -126,870 K. The company’s previous quarter sales were 24,220 K while its latest quarter income was -49,940 K.
